Cantor Fitzgerald L. P. Purchases Shares of 35,000 Abivax SA Sponsored ADR $ABVX

Cantor Fitzgerald L. P. acquired a new stake in Abivax SA Sponsored ADR (NASDAQ:ABVX) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 35,000 shares of the company’s stock, valued at approximately $2,972,000.

Several other institutional investors have also recently modified their holdings of the company. EverSource Wealth Advisors LLC lifted its holdings in shares of Abivax by 4,612.5% during the third quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock worth $32,000 after purchasing an additional 369 shares during the period. First Horizon Corp acquired a new position in Abivax in the 3rd quarter worth approximately $36,000. Hantz Financial Services Inc. purchased a new position in Abivax during the 3rd quarter worth approximately $52,000. Gordian Capital Singapore Pte Ltd purchased a new position in Abivax during the 3rd quarter worth approximately $76,000. Finally, Covestor Ltd acquired a new stake in Abivax during the 3rd quarter valued at approximately $96,000. 47.91% of the stock is currently owned by hedge funds and other institutional investors.

Abivax Trading Down 1.3%

Abivax stock opened at $115.50 on Friday. The firm has a market cap of $9.13 billion, a PE ratio of -27.63 and a beta of 1.00. Abivax SA Sponsored ADR has a 12 month low of $4.77 and a 12 month high of $148.83. The stock’s 50 day simple moving average is $118.99 and its two-hundred day simple moving average is $108.89. The company has a current ratio of 7.86, a quick ratio of 7.86 and a debt-to-equity ratio of 0.03.

Abivax (NASDAQ:ABVX) last posted its earnings results on Monday, December 15th. The company reported ($2.46) earnings per share for the quarter. The firm had revenue of ($4.92) million for the quarter. Analysts anticipate that Abivax SA Sponsored ADR will post -2.83 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Wedbush assumed coverage on shares of Abivax in a report on Tuesday, February 24th. They issued an “outperform” rating and a $110.00 price objective on the stock. Morgan Stanley raised their target price on shares of Abivax from $101.00 to $145.00 and gave the stock an “overweight” rating in a report on Friday, January 9th. Citigroup restated a “market outperform” rating on shares of Abivax in a research report on Thursday, January 8th. Piper Sandler reaffirmed an “overweight” rating and issued a $142.00 price target on shares of Abivax in a report on Tuesday, December 16th. Finally, Truist Financial set a $140.00 price target on Abivax in a research report on Monday, November 24th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $134.75.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.